Linus Angenendt

Muenster, NW 48149, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

Journal: Blood neoplasia
Published: June 09, 2025

Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysis.

Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysis.

Journal: EJHaem
Published: August 07, 2023

Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.

Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.

Journal: Blood
Published: June 29, 2023

Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears.

Deep learning predicts therapy-relevant genetics in acute myeloid leukemia from Pappenheim-stained bone marrow smears.

Journal: Blood advances
Published: June 28, 2023

Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.

Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.

Journal: Annals of hematology
Published: October 29, 2022

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.

Journal: Annals of hematology
Published: October 15, 2022

Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification.

Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification.

Journal: Blood
Published: September 29, 2022

Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia.

Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia.

Journal: Cell stem cell
Published: July 29, 2022

Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML).

Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML).

Journal: Annals of hematology
Published: May 17, 2022

Emerging antibody-based therapies for the treatment of acute myeloid leukemia.

Emerging antibody-based therapies for the treatment of acute myeloid leukemia.

Journal: Cancer treatment reviews
Published: February 06, 2022

Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia.

Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia.

Journal: Cancers
Published: December 30, 2021

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.

Journal: Blood advances
Published: December 23, 2021
Showing 1-12 of 40

Last Updated: 09/26/2026